Pharma Lobby Sues Trump Admin Over Medicare Drug Pricing Policy

Key Facts

The PhRMA lobbying group filed a lawsuit against the federal government challenging the most-favored-nation policy aimed at reducing Medicare drug prices. Reuters reported that the lawsuit alleges the program exceeds CMS authority and illegally imposes foreign price controls on domestic pharmaceuticals. The legal challenge seeks to block the administration's efforts to align domestic drug costs with lower international benchmarks.

The lobby argues the policy bypasses Congress and undermines medical innovation by implementing government price-setting schemes. Regarding market performance, PFE closed at $27.82 on October 8, 2026, and SNYNF closed at $79.94 on the same date. These legal challenges are viewed as a critical move by major manufacturers to protect profit margins against regulatory pricing interventions.